Multifaceted Role of Apolipoprotein C3 in Cardiovascular Disease Risk and Metabolic Disorder in Diabetes
International Journal of Molecular Sciences · 27.11.2024 · 25 (23) · 12759
DOI: 10.3390/ijms252312759 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.11.2024. Verfasst von Bo-Yi Pan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Biomedical Sciences, China Medical University, Taichung 40402, Taiwan. Hauptthemen laut MEDLINE: Apolipoprotein C-III, Cardiovascular Diseases, Diabetes Mellitus. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of Taiwan, China Medical University, Taiwan, China Medical University Hospital,Taiwan.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Apolipoprotein C3 (APOC3) plays a critical role in regulating triglyceride levels and serves as a key predictor of cardiovascular disease (CVD) risk, particularly in patients with diabetes. While APOC3 is known to inhibit lipoprotein lipase, recent findings reveal its broader influence across lipoprotein metabolism, where it modulates the structure and function of various lipoproteins. Therefore, this review examines the complex metabolic cycle of APOC3, emphasizing the impact of APOC3-containing lipoproteins on human metabolism, particularly in patients with diabetes. Notably, APOC3 affects triglyceride-rich lipoproteins and causes structural changes in high-, very low-, intermediate-, and low-density lipoproteins, thereby increasing CVD risk. Evidence suggests that elevated APOC3 levels—above the proposed safe range of 10–15 mg/dL—correlate with clinically significant CVD outcomes. Recognizing APOC3 as a promising biomarker for CVD, this review underscores the urgent need for high-throughput, clinically feasible methods to further investigate its role in lipoprotein physiology in both animal models and human studies. Additionally, we analyze the relationship between APOC3-related genes and lipoproteins, reinforcing the value of large-population studies to understand the impact of APOC3 on metabolic diseases. Ultimately, this review supports the development of therapeutic strategies targeting APOC3 reduction as a preventive approach for diabetes-related CVD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung 40402, Taiwan.
- The Ph.D. Program for Cancer Biology and Drug Discovery, China Medical University and Academia Sinica, Taichung 40402, Taiwan.
- Department of Medical Research, China Medical University Hospital, Taichung 40402, Taiwan.
- Department of Nursing, Asia University, Taichung 413305, Taiwan.
ORCID-Profile: Bo-Yi Pan, Chen-Sheng Chen, Ming-Yi Shen
Förderung
- Ministry of Science and Technology of Taiwan
- China Medical University, Taiwan
- China Medical University Hospital,Taiwan
- China Medical University
- China Medical University Hospital
Zitieren
APA
Pan, B. Y., Chen, C. S., Chen, F. Y., & Shen, M. Y. (2024). Multifaceted Role of Apolipoprotein C3 in Cardiovascular Disease Risk and Metabolic Disorder in Diabetes. International Journal of Molecular Sciences, 25(23), 12759. https://doi.org/10.3390/ijms252312759
Vancouver
Pan BY, Chen CS, Chen FY, Shen MY. Multifaceted Role of Apolipoprotein C3 in Cardiovascular Disease Risk and Metabolic Disorder in Diabetes. International Journal of Molecular Sciences. 2024;25(23):12759. doi:10.3390/ijms252312759
BibTeX
@article{Pan2024,
author = {Pan, Bo-Yi and Chen, Chen-Sheng and Chen, Fang-Yu and Shen, Ming-Yi},
title = {Multifaceted Role of Apolipoprotein C3 in Cardiovascular Disease Risk and Metabolic Disorder in Diabetes},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {23},
pages = {12759},
doi = {10.3390/ijms252312759}
}
EUVIMED